NewsEpisurf Medical Year-end Report 2016

Fourth quarter 2016 compared to 2015, Group

» Group net sales increased by 168% to SEK 1,007,759 (375,368).

» Other operating income amounted to SEK 821,447 (1,849,848) and is related to capitalized development costs.

» Loss for the period amounted to SEK -18,454,211 (-14,148,843).

» Earnings per share (weighted average) amounted to SEK -1,16 (-0.89).

Twelve months 2016, compared to 2015, Group

» Group net sales increased by 137% to SEK 2,405,614 (1,016,462).

» Other operating income amounted to SEK 1,859,976 (5,628,598) and is related to capitalized development costs.

» Loss for the period amounted to SEK -61,667,464 (-43,974,662).

» Earnings per share (weighted average) amounted to SEK -3,87 (-3,52).

» Equity per share was SEK 3,05 (6,89).

» Equity ratio was 80,8% (93,0).

Significant events during the fourth quarter

» Episurf Medical achieves milestone of 150th Implant.

» Episurf Medical’s 50th Episealer® Femoral Twin Implant demonstrates rapid clinical adoption.

» Touch surgery released Episealer surgical knee training simulations in collaboration with Episurf Medical.

Significant events after the fourth quarter

» Episurf Medical’s CEO Rosemary Cunningham Thomas steps down – search for new CEO initiated.

» Episurf Medical is expanding Its Clinical Advisory Board.

» Episurf Medical announces an up to approx. SEK 120 million rights issue subject to EGM approval and brings forward date of year-end report; Dennis Stripe to act as executive chairman.

» Episurf Medical obtains its first granted patents in China

» Episurf Medical’s 3D-based damage assessment tool: positive development in US patenting

Click on the link to download the full report >> http://episurf.com/investors/reports/

For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
E-mail: pal.ryfors@episurf.com